Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.
Hosokawa S, Ichihara E, Harada D, Kuyama S, Inoue K, Gemba K, Ichikawa H, Kato Y, Oda N, Oze I, Tamura T, Kozuki T, Umeno T, Kubo T, Hotta K, Bessho A, Maeda Y, Kiura K. Hosokawa S, et al. Among authors: maeda y. Int J Clin Oncol. 2022 Jul;27(7):1139-1144. doi: 10.1007/s10147-022-02164-2. Epub 2022 May 10. Int J Clin Oncol. 2022. PMID: 35534642 Clinical Trial.
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K, Kiura K. Tamura T, et al. Among authors: maeda y. Biochem Biophys Res Commun. 2018 Jan 1;495(1):360-367. doi: 10.1016/j.bbrc.2017.10.175. Epub 2017 Oct 31. Biochem Biophys Res Commun. 2018. PMID: 29101033
Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
Makimoto G, Ichihara E, Hotta K, Ninomiya K, Oze I, Minami D, Ninomiya T, Kubo T, Ohashi K, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: maeda y. Acta Med Okayama. 2018 Jun;72(3):319-323. doi: 10.18926/AMO/56080. Acta Med Okayama. 2018. PMID: 29926012 Free article. Clinical Trial.
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K. Kato Y, et al. Among authors: maeda y. Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11. Cancer Sci. 2018. PMID: 30053332 Free PMC article.
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K. Oda N, et al. Among authors: maeda y. Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1. Cancer Chemother Pharmacol. 2018. PMID: 30276451 Clinical Trial.
4,620 results